OST-577 human anti-hepatitis B monoclonal antibody data

PDLI reported that it saw reductions in key measures of hepatitis B after only a month of treatment in a Phase I/II open label trial in 12 patients with chronic active hepatitis B.

As reported

Read the full 353 word article

How to gain access

Continue reading with a
two-week free trial.